Financials
- Financial year
- 2025
- Total assets
- €242,189
- Loss
- -€280,766
- Solvency
- 90.5%
HEPHAISTOS-BELGIUM
ActiveSummary
The annual accounts of HEPHAISTOS-BELGIUM for financial year 2025 show a net loss of 116% of total assets. The 2025 annual accounts show equity of €219,234 and a net result of -€280,766. Its solvency ranks better than 88% of 271 sector peers (NACE 72, financial year 2025). The company has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Activity
Research and development on biotechnology
NACE 72101
1 site
Size
€242,189total assets 2025
- Staff
- 1.7 FTE
- Equity
- €219,234
- Loss
- -€280,766
Turnover not published (abbreviated format)
Structure
Accounts 23 days early
Why 56raises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €280,766 (financial year 2025)lowers riskLiquidity: current ratio 6.79, cash €150,277Sector: Scientific research and development (NACE 72)Equity €219,234 (90.5% of total assets)Show the evidence
Checked score
Score 2025
56
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 63% of its sector peers (NACE 72, micro)
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59. Every signal that counts is listed under Signals.
Financial strength
Strong
Solvency
100
equity 90.5% of total assets
Liquidity
100
short-term debt 9.5% · cash 62.0%
Profitability
0
return on assets -115.9%
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
10-2025: 0.7%
11-2025: 0.7%● unchanged vs 10-2025
12-2025: 0.7%● unchanged vs 11-2025
01-2026: 0.8%▲ +0.1 percentage points vs 12-2025
02-2026: 0.9%▲ +0.1 percentage points vs 01-2026
03-2026: 0.9%● unchanged vs 02-2026
04-2026: 1.0%▲ +0.1 percentage points vs 03-2026
05-2026: 1.0%● unchanged vs 04-2026highest value
06-2026: 1.0%● unchanged vs 05-2026
07-2026: 1.0%● unchanged vs 06-2026
08-2026: 0.1%▼ -0.9 percentage points vs 07-2026lowest value
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.2%▲ +0.1 percentage points vs 09-2026
Credit of up to €12,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity ample (current ratio 6.79, above the usual 1.5; short-term debt: 9.5% and cash: 62% of total assets), and 9.5% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro): better than 83% on solvency, 96% on liquidity and 10% on profitability.
The bankruptcy probability was computed on 20-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Young company
Founded in 2024, 2 years ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-07-2026, 23 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
23 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
- Annual accounts filedfinancial year 2025 · abbreviated…
- IncorporationAppointment: CAROFF Frédéric Nicolas Philippe…
Key points
By topic
Timeline
- Events
- 2
- Since
- 2024
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Research and development on biotechnologyNACE 72101
- Founded
- 06-09-2024
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 37
- Purpose
- “La recherche,le développement et la commercialisation de produits ou traitements…” (deed in French)
- Statutory auditor
- No statutory auditor
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Is the workforce growing, and do people stay?Employer check
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.